A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Quadrivalent Influenza Vaccine in Adults ≥65 Years of Age
Short Title/Acronym: N/A
Description:
Phase 3/3b efficacy study to demonstrate the efficacy of
the aQIV vaccine compared to an influenza comparator vaccine in the prevention of
laboratory-confirmed influenza A and/or B in adults aged 65 years and older.
Start Date: May 24, 2023
Eligibility:
This study will enroll male and female adults aged 65 years and older with no or stable comorbidities.